Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13594704 | 0.90 | PTGER4 (0.61) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2297565 | 0.86 | PTGER4 (0.72) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2431846 | 0.86 | PTGER4 (0.64) | PTGER4CYP1A2CYP2D6RXRARXRB | |
| SCHEMBL2426297 | 0.85 | PTGER4 (0.63) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3965044 | 0.85 | PTGER4 (0.71) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3963590 | 0.85 | PTGER4 (1.00) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2923324 | 0.84 | PTGER4 (0.72) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2929985 | 0.84 | PTGER4 (0.72) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3965548 | 0.83 | PTGER4 (0.72) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL14208630 | 0.82 | PTGER4 (0.64) | PTGER4CYP1A2CYP2D6RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | claimed |
| EP-2081896-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-07-29 | — | — | EP | claimed |
| WO-2008061955-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-05-29 | — | — | WO | claimed |
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | disclosed |
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | disclosed |
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | disclosed |
| WO-2008061955-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER3, HTR4 | PTGER4 1/4885CYP1A2 328/4885CYP2D6 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.